Research programme: tricyclic dextrocannabinoids - Pharmos
Latest Information Update: 22 Jul 2009
At a glance
- Originator Pharmos Corporation
- Class Cannabinoids
- Mechanism of Action Antioxidants; NMDA receptor antagonists; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 13 Jun 2006 Pharmos is seeking development partners for the dextrocannabinoid research programme
- 17 Apr 2001 Preclinical development for CNS disorders in USA (Unknown route)